Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi

4 Issues per year


CiteScore 2017: 2.48

SCImago Journal Rank (SJR) 2017: 1.021
Source Normalized Impact per Paper (SNIP) 2017: 0.830

Online
ISSN
1868-1891
See all formats and pricing
More options …
Volume 25, Issue 3

Issues

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study

Céline Bouchard / Fernand Labrie / Leonard Derogatis / Ginette Girard / Normand Ayotte / John Gallagher / Leonello Cusan / David F. Archer / David Portman / Lyne Lavoie / Adam Beauregard / Isabelle Côté / Céline Martel / Mario Vaillancourt / John Balser
  • Clinique de Recherche en Santé des Femmes, Quebec City, QC, Canada
  • Veristat, Holliston, MA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Erick Moyneur
  • Clinique de Recherche en Santé des Femmes, Quebec City, QC, Canada
  • StatLog Consulting Inc., Ottawa, ON, Canada
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ other participating Members of the VVA Prasterone Group
Published Online: 2015-12-18 | DOI: https://doi.org/10.1515/hmbci-2015-0044

Abstract

Objective: Intravaginal DHEA (dehydroepiandrosterone, prasterone), the exclusive precursor of androgens and estrogens in postmenopausal women, has previously been shown to improve all the domains of sexual function by a strictly local action in the vagina. The well recognized female sexual function index (FSFI) questionnaire was used in the present study.

Design: The long-term effect of 52-week treatment with daily intravaginal 0.50% (6.5 mg) DHEA was evaluated on the various domains of female sexual function using the FSFI questionnaire at baseline, Week 26 and Week 52.

Subjects: One hundred and fifty-four postmenopausal women with at least one mild to severe symptom of vulvovaginal atrophy (VVA) and who have completed the FSFI questionnaire at baseline and at least one post-baseline timepoint were included in the analysis.

Results: The FSFI domains desire, arousal, lubrication, orgasm, satisfaction and pain were increased by 28%, 49%, 115%, 51%, 41% and 108%, respectively (p<0.0001 for all parameters) at 52 weeks vs. baseline, while the total score was increased from 13.4±0.62 at baseline to 21.5±0.82 (+60%, p<0.0001) at 52 weeks.

Conclusion: As the serum levels of DHEA and all its metabolites, including estradiol and testosterone, show no meaningful change, the present clinical data indicate a stimulatory effect of intravaginal DHEA through a strictly local action in agreement with the preclinical data showing that the androgens made locally from DHEA in the vagina induce an increase in local nerve density.

Keywords: androgens; dehydroepiandrosterone (DHEA); female sexual dysfunction; FSFI; intracrinology; low arousal; low desire; postmenopause; prasterone; vaginal nerve fibers

References

  • 1.

    Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923–31.CrossrefGoogle Scholar

  • 2.

    Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med 2014;11:1766–85.CrossrefGoogle Scholar

  • 3.

    Pessina MA, Hoyt RF, Jr., Goldstein I, Traish AM. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology 2006;147:61–9.CrossrefGoogle Scholar

  • 4.

    Pelletier G, Ouellet J, Martel C, Labrie F. Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina. J Sex Med 2013;10:1908–14.CrossrefGoogle Scholar

  • 5.

    Pelletier G, Ouellet J, Martel C, Labrie F. Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal innervation in the rat. J Sex Med 2012;9:2525–33.CrossrefGoogle Scholar

  • 6.

    Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113–8.CrossrefGoogle Scholar

  • 7.

    Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric 2013;16:205–13.CrossrefGoogle Scholar

  • 8.

    Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011;18:30–43.CrossrefGoogle Scholar

  • 9.

    Labrie F. Androgens in postmenopausal women: their practically exclusive intracrine formation and inactivation in peripheral tissues. In: Plouffe L, Rizk B, editors. Androgens in Gynecological Practice, Cambridge University Press, 2015:64–73.Google Scholar

  • 10.

    Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897–906.CrossrefGoogle Scholar

  • 11.

    Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30–6.CrossrefGoogle Scholar

  • 12.

    Labrie F, Martel C, Bérubé R, Cote I, Labrie C, Cusan L, Gomez JL. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol 2013;138:359–67.CrossrefGoogle Scholar

  • 13.

    Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, participating Members of the prasterone clinical research G. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. J Steroid Biochem Mol Biol 2015;154:186–96.CrossrefGoogle Scholar

  • 14.

    Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol 2015;145:133–8.CrossrefGoogle Scholar

  • 15.

    Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez JL, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99:182–8.CrossrefGoogle Scholar

  • 16.

    Labrie F. DHEA after menopause – sole source of sex steroids and potential sex steroid deficiency treatment. Menopause Management 2010;19:14–24.Google Scholar

  • 17.

    Labrie F, Cusan L, Gomez JL, Martel C, Bérubé R, Bélanger P, Bélanger A, Vandenput L, Mellström D, Ohlsson C. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113:52–6.CrossrefGoogle Scholar

  • 18.

    Béjin A. Sexual pleasures, dysfunctions, fantaisies, and satisfaction. In: Spira A, Bajos N, editors. Sexual behaviour and AIDS aldershot. Aldershot, UK: Avebury, 1994:163–171.Google Scholar

  • 19.

    Kontula O, Haavio-Mannila E. Sexual pleasures. Enhancement of Sex Life in Finland, 1971–1992. Aldershot, UK: Dartmouth, 1995.Google Scholar

  • 20.

    Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006;24:2815–21.CrossrefGoogle Scholar

  • 21.

    Nathorst-Boos J, von Schoultz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 1992;34:97–101.CrossrefGoogle Scholar

  • 22.

    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537–44.CrossrefGoogle Scholar

  • 23.

    Osborn M, Hawton K, Gath D. Sexual dysfunction among middle aged women in the community. Br Med J (Clin Res Ed) 1988;296:959–62.CrossrefGoogle Scholar

  • 24.

    Hallstrom T. Sexuality in the climacteric. Clin Obstet Gynaecol 1977;4:227–39.Google Scholar

  • 25.

    Hallstrom T, Samuelsson S. Changes in women’s sexual desire in middle life: the longitudinal study of women in Gothenburg. Arch Sex Behav 1990;19:259–68.CrossrefGoogle Scholar

  • 26.

    Bancroft J, Cawood EH. Androgens and the menopause; a study of 40–60-year-old women. Clin Endocrinol (Oxf) 1996;45:577–87.CrossrefGoogle Scholar

  • 27.

    Avis NE, Stellato R, Crawford S, Johannes C, Longcope C. Is there an association between menopause status and sexual functioning? Menopause 2000;7:297–309.CrossrefGoogle Scholar

  • 28.

    Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001;76:456–60.CrossrefGoogle Scholar

  • 29.

    Dennerstein L, Smith AM, Morse CA, Burger HG. Sexuality and the menopause. J Psychosom Obstet Gynaecol 1994;15:59–66.CrossrefGoogle Scholar

  • 30.

    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Cote I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur E, Group MotVP. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015;81:46–56.CrossrefGoogle Scholar

  • 31.

    Ke Y, Gonthier R, Simard JN, Archer D, Lavoie L, Martel C, Vaillancourt M, Labrie F. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA. Horm Mol Biol Clin Invest 2015;24:117–29.Google Scholar

  • 32.

    Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dube R, other participating members of the VVAPG. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause 2015;22: 1289–95.CrossrefGoogle Scholar

  • 33.

    Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino RJ. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.CrossrefGoogle Scholar

  • 34.

    Meston CM. Validation of the female sexual function index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003;29:39–46.CrossrefGoogle Scholar

  • 35.

    Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1–20.CrossrefGoogle Scholar

  • 36.

    ter Kuile MM, Brauer M, Laan E. The female sexual function index (FSFI) and the female sexual distress scale (FSDS): psychometric properties within a dutch population. J Sex Marital Ther 2006;32:289–304.CrossrefGoogle Scholar

  • 37.

    Revicki DA, Margolis MK, Bush EN, DeRogatis LR, Hanes V. Content validity of the female sexual function index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2011;8:2237–45.CrossrefGoogle Scholar

  • 38.

    Bradford A, Meston CM. Placebo response in the treatment of women’s sexual dysfunctions: a review and commentary. J Sex Marital Ther 2009;35:164–81.CrossrefGoogle Scholar

  • 39.

    Bradford A, Meston CM. Behavior and symptom change among women treated with placebo for sexual dysfunction. J Sex Med 2011;8:191–201.CrossrefGoogle Scholar

  • 40.

    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating members of the VVAPG. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med 2015; In press.CrossrefGoogle Scholar

  • 41.

    Labrie F. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab 2007;3:584–93.CrossrefGoogle Scholar

  • 42.

    Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292:2243–48.CrossrefGoogle Scholar

  • 43.

    Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498–505.CrossrefGoogle Scholar

  • 44.

    Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227–36.CrossrefGoogle Scholar

  • 45.

    Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999;6:138–46.CrossrefGoogle Scholar

  • 46.

    Labrie F. DHEA, important source of sex steroids in men and even more in women. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff D, editors: Neuroendocrinology, the normal neuroendocrine system, progress in brain research. Amsterdam, The Netherlands: Elsevier. 2010, vol 182 (Chapter 4):97–148.Google Scholar

  • 47.

    Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153–60.CrossrefGoogle Scholar

  • 48.

    Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397–409.CrossrefGoogle Scholar

  • 49.

    Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 2008;11:181–91.CrossrefGoogle Scholar

  • 50.

    Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341–52.CrossrefGoogle Scholar

  • 51.

    Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000;57:149–53; discussion 155–146.CrossrefGoogle Scholar

  • 52.

    Tuiten A, van Honk J, Verbaten R, Laan E, Everaerd W, Stam H. Can sublingual testosterone increase subjective and physiological measures of laboratory-induced sexual arousal? Arch Gen Psychiatry 2002;59:465–6.CrossrefGoogle Scholar

  • 53.

    Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390–8.CrossrefGoogle Scholar

  • 54.

    Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med 1998;43:847–56.Google Scholar

  • 55.

    Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O’Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006;13:770–9.CrossrefGoogle Scholar

  • 56.

    Davis SR, Tran J. Testosterone influences libido and well being in women. Trends Endocrinol Metab 2001;12:33–7.CrossrefGoogle Scholar

  • 57.

    Hulter B, Lundberg PO. Sexual function in women with hypothalamo-pituitary disorders. Arch Sex Behav 1994;23:171–83.CrossrefGoogle Scholar

  • 58.

    Basson R. Hormones and sexuality: current complexities and future directions. Maturitas 2007;57:66–70.CrossrefGoogle Scholar

  • 59.

    Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70:1124–31.CrossrefGoogle Scholar

  • 60.

    Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab 2008;93:801–8.CrossrefGoogle Scholar

  • 61.

    Basson R, Brotto LA, Petkau AJ, Labrie F. Role of androgens in women’s sexual dysfunction. Menopause 2010;17:962–71.CrossrefGoogle Scholar

  • 62.

    Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91–6.CrossrefGoogle Scholar

  • 63.

    Genazzani AR, Pluchino N. DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence. Climacteric 2010;13:314–6.CrossrefGoogle Scholar

  • 64.

    Gracia CR, Freeman EW, Sammel MD, Lin H, Mogul M. Hormones and sexuality during transition to menopause. Obstet Gynecol 2007;109:831–40.CrossrefGoogle Scholar

  • 65.

    Sand M, Rosen R, Meston C, Brotto LA. The female sexual function index (FSFI): a potential “gold standard” measure for assessing therapeutically-induced change in female sexual function. Fertil Steril 2009;92:Suppl S129, P-145.CrossrefGoogle Scholar

  • 66.

    Gerstenberger EP, Rosen RC, Brewer JV, Meston CM, Brotto LA, Wiegel M, Sand M. Sexual desire and the female sexual function index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med 2010;7:3096–103.CrossrefGoogle Scholar

  • 67.

    Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2012;119:527–38.CrossrefGoogle Scholar

  • 68.

    Chedraui P, Perez-Lopez FR, San Miguel G, Avila C. Assessment of sexuality among middle-aged women using the female sexual function index. Climacteric 2009;12:213–21.CrossrefGoogle Scholar

  • 69.

    Berra M, De Musso F, Matteucci C, Martelli V, Perrone AM, Pelusi C, Pelusi G, Meriggiola MC. The impairment of sexual function is less distressing for menopausal than for premenopausal women. J Sex Med 2010;7:1209–15.CrossrefGoogle Scholar

  • 70.

    Nappi RE, Albani F, Santamaria V, Tonani S, Magri F, Martini E, Chiovato L, Polatti F. Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas 2010;67:78–83.CrossrefGoogle Scholar

  • 71.

    Blumel JE, Bravo F, Recavarren M, Sarra S. [Sexual function in postmenopausal women using hormone replacement therapy]. Rev Med Chil 2003;131:1251–5.Google Scholar

  • 72.

    Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, Freeman EW, Larson JC, Manson JE, LaCroix AZ, Guthrie KA. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstet Gynecol 2014;124:233–41.CrossrefGoogle Scholar

  • 73.

    Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, Helmond FA, Van Lunsen RH, Palacios S, Norman RJ, Mulder RJ, Davis SR. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646–56.CrossrefGoogle Scholar

  • 74.

    Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 2000;3:176–82.Google Scholar

  • 75.

    Dennerstein L, Guthrie JR, Hayes RD, DeRogatis LR, Lehert P. Sexual function, dysfunction, and sexual distress in a prospective, population-based sample of mid-aged, Australian-born women. J Sex Med 2008;5:2291–9.CrossrefGoogle Scholar

  • 76.

    Manson JE. The Kronos early estrogen prevention study by charlotte barker. Womens Health (Lond Engl) 2013;9:9–11.CrossrefGoogle Scholar

  • 77.

    Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196:97–106.CrossrefGoogle Scholar

  • 78.

    Blumel JE, Del Pino M, Aprikian D, Vallejo S, Sarra S, Castelo-Branco C. Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecol Endocrinol 2008;24:691–5.CrossrefGoogle Scholar

  • 79.

    Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia MJ, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014;21:633–40.CrossrefGoogle Scholar

  • 80.

    Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015;18:226–32.CrossrefGoogle Scholar

  • 81.

    Nappi RE, Polatti F. The use of estrogen therapy in women’s sexual functioning (CME). J Sex Med 2009;6:603–16; quiz 618–609.CrossrefGoogle Scholar

  • 82.

    Bertin J, Ouellet J, Dury AY, Pelletier G, Labrie F. Expression of the estrogen receptors and steroidogenic enzymes involved in estradiol formation in the monkey vagina. Am J Obstet Gynecol 2014;211:e1–9.CrossrefGoogle Scholar

  • 83.

    Bertin J, Dury AY, Ouellet J, Pelletier G, Labrie F. Localization of the androgen-synthesizing enzymes, androgen receptor and sex steroids in the vagina: possible implications for the treatment of postmenopausal sexual dysfunction. J Sex Med 2014;11:1949–61.CrossrefGoogle Scholar

  • 84.

    Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, premarin and acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005;96:201–15.CrossrefGoogle Scholar

  • 85.

    Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone) a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907–22.CrossrefGoogle Scholar

  • 86.

    Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (DHEA, Prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282–8.CrossrefGoogle Scholar

  • 87.

    Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J, other participating members of the VVAPG. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepaindrosterone (prasterone). Menopause 2015;22:950–63.CrossrefGoogle Scholar

  • 88.

    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman DJ, Montessino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating members of the VVAPG. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy and of the genitourinary syndrome of menopause. Menopause, DOI: 10.1111/jsm.13045, (In press).CrossrefGoogle Scholar

About the article

Corresponding author: Fernand Labrie, EndoCeutics Inc., 2795 Laurier Blvd, Suite 500, Quebec City (Quebec) G1V 4M7, Canada, Phone: +1-418-653-0055, Fax: +1-418-653-3635, E-mail:


Received: 2015-09-22

Accepted: 2015-11-09

Published Online: 2015-12-18

Published in Print: 2016-03-01


Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 25, Issue 3, Pages 181–190, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: https://doi.org/10.1515/hmbci-2015-0044.

Export Citation

©2016 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Carly S. Sears, John W. Robinson, and Lauren M. Walker
European Journal of Cancer Care, 2017, Page e12738

Comments (0)

Please log in or register to comment.
Log in